Helical's thesis is that bio foundation models, AI systems trained on vast genomic, transcriptomic, and proteomic datasets, have already crossed a quality threshold that makes computational hypothesis-testing meaningful in pharma research.
"What turned out to be useful is that I got to learn a lot about history and a lot about the kind of stories that we tell ourselves about the future. That's turned out to be like, extremely relevant for AI in a way that I think people wouldn't have predicted."
For many years, PyCon US has relied on hotel booking commissions to help pay for our conference space. This helps us keep the event tickets affordable and to continue offering Travel Grants to community members who might not otherwise be able to attend PyCon US.
The SFPD's Special Investigation Division took over the case and have since detained both 25-year-old Amanda Tom and 23-year-old Muhamad Tarik Hussein, seizing three firearms in the process with the help of a warrant.
Novo Nordisk plans to deploy advanced artificial intelligence capabilities to analyze complex datasets, identify promising drug candidates, and reduce the time required to move from research to patient.
Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.
But he'd been considering an idea for new technology-an autonomous, wind-powered cargo ship. Then, while on paternity leave in 2024, he discovered a free program that helps scientists and engineers launch businesses for the first time. Weeks after finishing the program, called 5050, Cymbalist had launched a startup called Clippership. The company's first ship is being built in the Netherlands this year. Without the accelerator, he says, the company likely wouldn't exist.
Martschenko's argument is largely that genetic research and data have almost always been used thus far as a justification to further entrench extant social inequalities. But we know the solutions to many of the injustices in our world-trying to lift people out of poverty, for example-and we certainly don't need more genetic research to implement them. Trejo's point is largely that more information is generally better than less.
